nach oben

11.06.2019

The Protective Effect of Crataegus aronia Against High-Fat Diet-Induced Vascular Inflammation in Rats Entails Inhibition of the NLRP-3 Inflammasome Pathway

verfasst von: Abdullah S. Shatoor, Suliman Al Humayed

Erschienen in: Cardiovascular Toxicology

Einloggen, um Zugang zu erhalten

Abstract

This study investigated whether the whole-plant aqueous extract of Crataegus aronia (C. aronia) could protect against or alleviate high-fat diet (HFD)-induced aortic vascular inflammation in rats by inhibiting the NLRP-3 inflammasome pathway and examined some mechanisms of action with respect to its antioxidant and hypolipidemic effects. Adult male Wistar rats were divided into five groups (n = 6/each): standard diet (10% fat) fed to control rats, control + C. aronia (200 mg/kg), HFD (40% fat), HFD + C. aronia, and HFD post-treated with C. aronia. The HFD was fed for 8 weeks and C. aronia was administered orally for 4 weeks. In addition, isolated macrophages from control rats were pre-incubated with two doses of C. aronia (25 and 50 μg/mL) with or without lipopolysaccharide (LPS) stimulation. Only in HFD-fed rats, co- and post-C. aronia therapy lowered circulatory levels of LDL-C and ox-LDL-c and aortic protein levels of LOX-1 and CD36. C. aronia also inhibited the nuclear accumulation of NF-κB and lowered protein levels of NLRP-3, caspase-1, and mature IL-1β. In vitro, in the absence of ox-LDL-c, C. aronia led to reduced nuclear levels of NF-κB, ROS generation, and protein NLRP-3 levels, in both LPS-stimulated and unstimulated macrophages, in a dose-dependent manner. However, protein levels of LOX-1 were not affected by C. aronia in unstimulated cells. In conclusion, C. aronia inhibits the NLRP-3 inflammasome pathway, induced by HFD feeding in the aorta of rats, mainly by its hypolipidemic effect and in vitro, in LPS-stimulated macrophages, by its antioxidant effect.

Graphic Abstract

Packard, R. R., & Libby, P. (2008). Inflammation in atherosclerosis: From vascular biology to biomarker discovery and risk prediction. Clinical Chemistry,54, 24–38.PubMed

Anogeianaki, A., Angelucci, D., Cianchetti, E., D’Alessandro, M., Maccauro, G., Saggini, A., et al. (2011). Atherosclerosis: A classic inflammatory disease. International Journal of Immunopathology and Pharmacology,24(4), 817–825.PubMed

Tedgui, A., & Mallat, Z. (2006). Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiological Reviews,86(2), 515–581.PubMed

Baldrighi, M., Malla, Z., & Li, X. (2017). NLRP-3 inflammasome pathways in atherosclerosis. Atherosclerosis,267, 127–138.PubMed

Libby, P. (2017). Interleukin-1 beta as a target for atherosclerosis therapy biological basis of CANTOS and beyond. Journal of the American College of Cardiology,70, 2278–2289.PubMedPubMedCentral

Shi, X., Xie, W. L., Kong, W. W., Chen, D., & Qu, P. (2015). Expression of the NLRP-3 inflammasome in carotid atherosclerosis. Journal of Stroke and Cerebrovascular Diseases,24, 2455–2466.PubMed

Paramel Varghese, G., Folkersen, L., Strawbridge, R. J., Halvorsen, B., Yndestad, A., Ranheim, T., et al. (2016). NLRP-3 inflammasome expression and activation in human atherosclerosis. Journal of the American Heart Association,5, e003031.PubMedPubMedCentral

Xing, Q. (2014). Silence of NLRP-3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Mediators of Inflammation,2014, 507208.PubMedPubMedCentral

Kirichenko, T. V., Sobenin, I. A., Nikolic, D., Rizzo, M., & Orekhov, A. N. (2016). Anticytokine therapy for prevention of atherosclerosis. Phytomedicine,23(11), 1198–1210.PubMed

10.

Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine,377(12), 1119–1131.PubMed

11.

Zheng, H., Fletcher, D., Kozak, W., Jiang, M., Hofmann, K. J., Conn, C. A., et al. (1995). Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity,3(1), 9–19.PubMed

12.

Abderrazak, A., Couchie, D., Mahmood, D. F., Elhage, R., Vindis, C., Laffargue, M., et al. (2015). Antiinflammatory and antiatherogenic effects of the NLRP-3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation,131(12), 1061–1070.PubMed

13.

Chang, W. T., Dao, J., & Shao, Z. H. (2005). Hawthorn: Potential roles in cardiovascular disease. The American Journal of Chinese Medicine,33(1), 1–10.PubMed

14.

Wang, J., Xiong, X., & Feng, B. (2013). Effect of crataegus usage in cardiovascular disease prevention: An evidence-based approach. Evidence-Based Complement Alternat Med.,2013, 149363.

15.

Nabavi, S. F., Habtemariam, S., Ahmed, T., Sureda, A., Daglia, M., Sobarzo-Sánchez, E., et al. (2015). Polyphenolic composition of Crataegus monogyna Jacq: From chemistry to medical applications. Nutrients,7(9), 708–728.

16.

Gao, P., Li, S., Liu, K., Sun, C., Song, S., & Li, L. (2019). Antiplatelet aggregation and antithrombotic benefits of terpenes and flavones from hawthorn leaf extract isolated using the activity-guided Method. Food and Function,10(20), 859–866.PubMed

17.

Liu, P., Yang, B., & Kallio, H. (2010). Characterization of phenolic compounds in Chinese hawthorn (Crataegus pinnatifida Bge. var. major) fruit by high-performance liquid chromatography–electrospray ionization mass spectrometry. Food Chemistry,121(4), 1188–1197.

18.

Fong, H. H. S., & Bauman, J. L. (2002). Hawthorn. The Journal of Cardiovascular Nursing,16(4), 1–8.PubMed

19.

Attard, E., & Attard, H. (2006). The potential angiotensin-converting enzyme inhibitory activity of oleanolic acid in the hydroethanolic extract of Crataegus monogyna Jacq. Natural Product Communications,1, 381–386.

20.

Petkov, E., Nikolov, N., & Uzunov, P. (1981). Inhibitory effect of some flavonoids and flavonoid mixtures on cyclic AMP phosphodiesterase activity of rat heart. Planta Medica,43(2), 183–186.PubMed

21.

Schwinger, R. H., Pietsch, M., Frank, K., & Brixius, K. (2000). Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. Journal of Cardiovascular Pharmacology,35(5), 700–707.PubMed

22.

Chen, Z. Y., Zhang, Z. S., Kwan, K. Y., Zhu, M., Ho, W. K., & Huang, Y. (1998). Endothelium-dependent relaxation induced by hawthorn extract in rat mesenteric artery. Life Sciences,63(22), 1983–1991.PubMed

23.

Kim, S. H., Kang, K. W., Kim, K. W., & Kim, N. D. (2000). Procyanidins in crataegus extract evoke endothelium-dependent vasorelaxation in rat aorta. Life Sciences,67(2), 121–131.PubMed

24.

Pittler, M. H., Schmidt, K., & Ernst, E. (2008). Hawthorn extract for treating chronic heart failure. Cochrane Database of Systematic Reviews,23(1), CD005312.

25.

Veveris, M., Koch, E., & Chatterjee, S. S. (2004). Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sciences,74, 1945–1955.PubMed

26.

Müller, A., Linke, W., Zhao, Y., & Klaus, W. (1996). Crataegus extract prolongs action potential duration in guinea-pig papillary muscle. Phytomedicine,3(3), 257–261.PubMed

27.

Müller, A., Linke, W., & Klaus, W. (1999). Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Medica,65(4), 335–339.PubMed

28.

Garjani, A., Nazemiyeh, H., Maleki, N., & Valizadeh, H. (2000). Effects of extracts from flowering tops of Crataegus meyeri A. Pojark. on ischaemic arrhythmias in anaesthetized rats. Phytotherapy Research,14(6), 428–431.PubMed

29.

Rajendran, S., Deepalakshm, P. D., Parasakthy, K., Devaraj, H., & Devaraj, S. N. (1996). Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis.,123(1–2), 235–241.PubMed

30.

Zhang, Z., Ho, W. K., Huang, Y., James, A. E., Lam, L. W., & Chen, Z. Y. (2002). Hawthorn fruit is hypolipidemic in rabbits fed a high cholesterol diet. The Journal of Nutrition,132(1), 5–10.PubMed

31.

Shih, C. C., Lin, C. H., Lin, Y. J., & Wu, J. B. (2013). Validation of the antidiabetic and hypolipidemic effects of hawthorn by assessment of gluconeogenesis and lipogenesis related genes and AMP-activated protein kinase phosphorylation. Evidence-Based Complementary and Alternative Medicine.,2013, 597067.PubMedPubMedCentral

32.

Kao, E., Wang, C., Lin, W., Yin, Y., Wang, C., & Tseng, T. (2005). Anti-inflammatory potential of flavonoid contents from dried fruit of Crataegus pinnatifida in vitro and in vivo. Journal of Agricultural and Food Chemistry,53(2), 430–436.PubMed

33.

Chu, C., Lee, M., Liao, C., Lin, W., Yin, Y., & Tseng, T. (2003). Inhibitory effect of hot water extract from dried fruit of Crataegus pinnatifida on low-density lipoprotein (LDL) oxidation in cell and cell-free systems. Journal of Agricultural and Food Chemistry,51(26), 7583.PubMed

34.

Fu, J. H., Zheng, Y. Q., Li, P., Li, X. Z., Shang, X. H., & Liu, J. X. (2013). Hawthorn leaves flavonoids decreases inflammation related to acute myocardialischemia/reperfusion in anesthetized dogs. Chinese Journal of Integrative Medicine,19(8), 582–588.PubMed

35.

Ljubuncic, P., Portnaya, I., Cogan, U., Azaizeh, H., & Bomzon, A. (2005). Antioxidant activity of Crataegus aronia aqueous extract used in traditional Arab medicine in Israel. Journal of Ethnopharmacology,101(1–3), 153–161.PubMed

36.

Shatoor, A. S. (2011). Acute and sub-acute toxicity of Crataegus aronia syn Azarolus (L.) whole plant aqueous extract in wistar rats. American Journal of Pharmacology Toxicology.,6, 37–45.

37.

Shatoor, A. S. (2013). In vivo hemodynamic and electrocardiographic changes following Crataegus aronia syn. Azarolus (L.) administration to normotensive Wistar rats. Saudi Medical Journal,34(2), 123–134.PubMed

38.

Humayed, S. (2017). Protective and therapeutic effects of Crataegus aronia in non-alcoholic fatty liver disease. Archives of Physiology and Biochemistry,123(1), 23–30.PubMed

39.

Dallak, M. (2018). Crataegus aronia enhances sperm parameters and preserves testicular architecture in both control and non-alcoholic fatty liver disease-induced rats. Pharmaceutical Biology,56(1), 535–547.PubMedPubMedCentral

40.

Mostafa, D. G., Khaleel, E. F., & Abdel-Aleem, G. A. (2018). Inhibition of the hepatic glucose output is responsible for the hypoglycemic effect of Crataegus aronia against type 2 diabetes mellitus in rats. Archives of Biological Sciences,70(2), 277–287.

41.

Shatoor, A. S., Al Humayed, S., Alkhateeb, M. A., Shatoor, A. K., Aldera, H., Alassiri, M., et al. (2019). Crataegus Aronia protects and reverses vascular inflammation in a high-fat diet rat model by an antioxidant mechanism and modulating serum levels of oxidized low-density lipoprotein. Pharmaceutical Biology,57(1), 38–48.PubMedPubMedCentral

42.

Begue, G., Douillard, A., Galbes, O., Rossano, B., Vernus, B., Candau, R., et al. (2013). Activation of rat skeletal muscle IL-6/STAT1/STAT3 dependent gene expression in resistance exercise linked to hypertrophy. PLoS ONE,8, e57141.PubMedPubMedCentral

43.

Boaru, S. G., Borkham-Kamphorst, E., Tihaa, L., Haas, U., & Weiskirchen, R. (2012). Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. Journal of Inflammation,9(1), 49.PubMed

44.

Veres-Székely, A., Pap, D., Sziksz, E., Jávorszky, E., Rokonay, R., Lippai, R., et al. (2017). Selective measurement of α smooth muscle actin: Why β-actin can not be used as a housekeeping gene when tissue fibrosis occurs. BMC Molecular Biology,18(1), 12.PubMedPubMedCentral

45.

Xie, S., Xie, S., Liu, B., Fu, S., Wang, W., Yin, Y., et al. (2014). GLP-2 suppresses LPS-induced inflammation in macrophages by inhibiting ERK phosphorylation and NF-κB activation. Cellular Physiology and Biochemistry,34(2), 590–602.PubMed

46.

Soromou, L. W., Zhang, Z., Li, R., Chen, N., Guo, W., Huo, M., et al. (2012). Regulation of inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine macrophage by 7-O-methyl-naringenin. Molecules,17(3), 3574–3585.PubMedPubMedCentral

47.

Sheehan, D. C., & Hrapchak, B. B. (1987). Theory and practice of histotechnology (2nd ed.). Columbus: Battelle Memorial Institute.

48.

Li, D., & Mehta, J. L. (2000). Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of coronary artery endothelial cells: Evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology,20(4), 1116–1122.PubMed

49.

Ding, Z., Liu, S., Wang, X., Dai, Y., Khaidakov, M., Deng, X., et al. (2014). LOX-1, mtDNA damage, and NLRP-3 inflammasome activation in macrophages: Implications in atherogenesis. Cardiovascular Research,103(4), 619–628.PubMedPubMedCentral

50.

Ferreiro, D. U., & Komives, E. A. (2010). Molecular mechanisms of system control of NF-κB signaling by IκBα. Biochemistry,49(8), 1560–1567.PubMedPubMedCentral

51.

Groot, P. H., van Vlijmen, B. J., Benson, G. M., Hofker, M. H., Schiffelers, R., Vidgeon-Hart, M., et al. (1996). Quantitative assessment of aortic atherosclerosis in APOE3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arteriosclerosis, Thrombosis, and Vascular Biology,16(8), 926–933.PubMed

52.

Jawien, J., Csanyi, G., Gajda, M., Mateuszuk, L., Lomnicka, M., Korbut, R., et al. (2007). Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. European Journal of Pharmacology,556(1–3), 129–135.PubMed

53.

Wrobel, P. T., Mateuszuk, L., Chlopicki, S., Malek, K., & Baranska, M. (2011). Imaging of lipids in atherosclerotic lesion in aorta from ApoE/LDLR-/- mice by FT-IR spectroscopy and hierarchical cluster analysis. Analyst.,136(24), 5247–5255.

54.

Lloyd, D. J., Helmering, J., Kaufman, S. A., Turk, J., Silva, M., Vasquez, S., et al. (2011). A volumetric method for quantifying atherosclerosis in mice by using microCT:comparison to en face. PLoS ONE,6(4), e18800.PubMedPubMedCentral

55.

Mackness, M. I., Arrol, S., & Durrington, P. N. (1991). Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letters,286(1–2), 152–154.PubMed

56.

Khalil, R., Abuharfeil, N., & Shabsoug, B. (2008). The effect of Crataegus Aronica aqueous extract in rabbits fed with high cholesterol diet. European Journal of Scientific Research.,22(3), 352–360.

57.

Pirillo, A., Norata, G. D., & Catapano, A. L. (2013). LOX-1, oxLDL, and atherosclerosis. Mediators of Inflammation,2013, 152786.PubMedPubMedCentral

58.

Kotla, S., Singh, N. K., & Rao, G. N. (2017). ROS via BTK-p300-STAT1-PPARg signaling activation mediates cholesterol crystals-induced CD36 expression and foam cell formation. Redox Biology,11, 350–364.PubMed

59.

Thacker, S. G., Zarzour, A., Chen, Y., Alcicek, M. S., Freeman, L. A., Sviridov, D. O., et al. (2016). High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation. Immunology,149(3), 306–319.PubMedPubMedCentral

60.

Zhang, Z., Chang, Q., Zhu, M., Huang, Y., Ho, W. K., & Chen, Z. (2001). Characterization of antioxidants present in hawthorn fruits. The Journal of Nutritional Biochemistry,12(3), 144–152.PubMed

61.

Bahri-Sahloul, R., Ben Fredj, R., Boughalleb, N., Shriaa, J., Saguem, S., Hilbert, J. L., et al. (2014). Phenolic composition and antioxidant and antimicrobial activities of extracts obtained from Crataegus azarolus L. var. aronia (Willd.) Batt Ovaries Calli. Journal of Botany.,2014, 623651.

62.

Liu, P., Kallio, H., & Yang, B. (2011). Phenolic compounds in hawthorn (Crataegus grayana) fruits and leaves and changes during fruit ripening. Journal of Agricultural and Food Chemistry,59(20), 11141–11149.PubMed

63.

Gao, P. Y., Li, L. Z., Liu, L. C., Sun, C., Sun, X., Wu, T. N., et al. (2017). Natural terpenoid glycosides with in vitro/vivo antithrombotic profiles from the leaves of Crataegus pinnatifida. RSC Advances,76, 48466–48474.

64.

Lin, Y., Vermeer, M. A., & Trautwein, E. A. (2011). Triterpenic acids present in hawthorn lower plasma cholesterol by inhibiting intestinal ACAT activity in hamsters. Evidence-Based Complementary and Alternative Medicine.,2011, 801272.PubMed

65.

de Whalley, C. V., Rankin, S. M., Hoult, J. R., Jessup, W., & Leake, D. S. (1990). Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochemical Pharmacology,39(11), 1743–1750.PubMed

66.

Bahri-Sahloul, R., Ammar, S., Fredj, R. B., Saguem, S., Grec, S., Trotin, F., et al. (2009). Polyphenol contents and antioxidant activities of extracts from flowers of two Crataegus azarolus L. varieties. Pakistan Journal of Biological Sciences,12(9), 660–668.PubMed

67.

Meng, S., Cao, J., Feng, Q., Peng, J., & Hu, Y. (2013). Roles of chlorogenic acid in regulating glucose and lipids metabolism: A review. Evidence-Based Complementary and Alternative Medicine,801457, 31.

68.

Quettier-Deleu, C., Voiselle, G., Fruchart, J. C., Duriez, P., Teissier, E., Bailleul, F., et al. (2003). Hawthorn extracts inhibit LDL oxidation. Pharmazie.,58(8), 577–581.PubMed

Titel: The Protective Effect of Crataegus aronia Against High-Fat Diet-Induced Vascular Inflammation in Rats Entails Inhibition of the NLRP-3 Inflammasome Pathway
verfasst von: Abdullah S. Shatoor
Suliman Al Humayed
Publikationsdatum: 11.06.2019
Verlag: Springer US
Erschienen in: Cardiovascular Toxicology
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-019-09534-9

Springer Medizin

Abstract

Graphic Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten